Research Article | | Peer-Reviewed

Evaluation of the Antihyperglycemic Activity of Ethanolic Extracts of Syzygium tamilnadense in Nicotinamide–Streptozotocin-Induced Type 2 Diabetic Rats

Received: 13 July 2026     Accepted: 27 July 2026     Published: 27 August 2026
Views:       Downloads:
Abstract

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. Prolonged hyperglycemia is associated with oxidative stress, dyslipidemia, and progressive damage to vital organs, highlighting the need for safer and more effective therapeutic agents. Syzygium tamilnadense Rathakr. & Chitra, an endemic medicinal species of the Western Ghats, India, has been traditionally used for various therapeutic purposes; however, its antidiabetic potential has not been scientifically validated. To the best of our knowledge, this is the first scientific exploration of its medicinal potential. The present study aimed to evaluate the antihyperglycemic, antioxidant, and organ-protective effects of the ethanolic extract of S. tamilnadense in nicotinamide–streptozotocin-induced type 2 diabetic rats. Experimental diabetes was induced using nicotinamide and streptozotocin, followed by oral administration of different doses of the ethanolic extract for four weeks. Fasting blood glucose, oral glucose tolerance, glycated hemoglobin (HbA1c), serum insulin, hepatic glycogen, lipid profile, antioxidant enzymes, hepatic and renal function biomarkers, and histopathological changes in pancreatic and hepatic tissues were evaluated. Treatment with S. tamilnadense significantly reduced fasting blood glucose and HbA1c levels, improved glucose tolerance, restored serum insulin and hepatic glycogen levels, normalized serum lipid profiles, and enhanced body weight compared with diabetic controls. The extract also improved endogenous antioxidant defense, attenuated oxidative stress, and significantly ameliorated hepatic and renal dysfunction. Histopathological examination further demonstrated marked regeneration of pancreatic β-cells and restoration of normal hepatic architecture in treated animals. The higher-dose treatment exhibited therapeutic efficacy comparable to the standard antidiabetic drug. These findings demonstrate that the ethanolic extract of S. tamilnadense possesses significant antihyperglycemic, antioxidant, hepatoprotective, and nephroprotective activities, suggesting its potential as a promising natural therapeutic candidate for the management of type 2 diabetes mellitus. Further studies are warranted to isolate the bioactive constituents and elucidate the underlying molecular mechanisms.

Published in Journal of Diseases and Medicinal Plants (Volume 12, Issue 3)
DOI 10.11648/j.jdmp.20261203.13
Page(s) 117-127
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2026. Published by Science Publishing Group

Keywords

Syzygium tamilnadense Nicotinamide–streptozotocin (STZ), HbA1c, Antihyperglycemic, Antihyperlipidemic

1. Introduction
Diabetes mellitus (DM) is one of the most common chronic metabolic disorders worldwide and a major public health concern. It is characterized by persistent hyperglycemia caused by impaired insulin secretion, insulin action, or both, resulting in abnormalities in carbohydrate, lipid, and protein metabolism. Type 2 diabetes mellitus (T2DM) accounts for approximately 90–95% of all diabetes cases and is strongly associated with obesity, sedentary lifestyle, and genetic susceptibility. Prolonged hyperglycemia promotes oxidative stress, inflammation, and metabolic dysfunction, leading to complications involving the liver, kidneys, cardiovascular system, nervous system, and pancreas . Although insulin and oral hypoglycemic agents such as metformin and sulfonylureas effectively regulate blood glucose, their long-term use is often limited by adverse effects, including hypoglycemia, gastrointestinal disturbances, weight gain, and declining efficacy. Consequently, medicinal plants have gained considerable attention as alternative or complementary therapies because of their multitarget pharmacological actions, lower toxicity, and wide availability. Bioactive phytochemicals, including flavonoids, phenolic acids, tannins, alkaloids, and terpenoids, possess antihyperglycemic, antioxidant, anti-inflammatory, and insulin-sensitizing properties, highlighting their therapeutic potential in diabetes management .
The genus Syzygium (Myrtaceae), comprising over 1,200 tropical and subtropical species, is well known for its medicinal value, with several species, particularly Syzygium cumini, exhibiting antidiabetic, antioxidant, antimicrobial, anti-inflammatory, hepatoprotective, and nephroprotective activities attributed to their rich polyphenol and flavonoid content . Syzygium tamilnadense Rathakr. & Chitra is a rare endemic tree restricted to the shola forests of the Nilgiri Biosphere Reserve, Western Ghats, India . Despite preliminary evidence of its phytochemical richness and antioxidant potential, its antidiabetic efficacy has not been comprehensively investigated, particularly regarding glucose homeostasis, carbohydrate metabolism, oxidative stress, lipid metabolism, hepatic and renal biomarkers, antioxidant defense, and histopathological changes. Therefore, the present study evaluated the antihyperglycemic, antioxidant, hepatoprotective, and nephroprotective effects of the ethanolic extract of S. tamilnadense in nicotinamide–streptozotocin-induced type 2 diabetic rats by assessing fasting blood glucose, oral glucose tolerance, glycated hemoglobin (HbA1c), serum insulin, hepatic glycogen, lipid profile, liver and kidney function markers, antioxidant status, carbohydrate-metabolizing enzymes, hematological parameters, and pancreatic and hepatic histopathology. The findings provide experimental evidence supporting the therapeutic potential of this endemic species as a promising plant-based intervention for type 2 diabetes mellitus.
2. Materials and Methods
2.1. Chemicals
Streptozotocin (500 mg, S-0130, Sigma-Aldrich), Nicotinamide (100 g, N-3376, Sigma-Aldrich), Sodium Citrate (Mw: 294.10), Citric Acid (Mw: 210.10), Sucrose 10%, Distillate water, Sodium chloride (NaCl 0.9%).
2.2. Plant Material and Extract Preparation
Fresh leaf and fruit samples of the experimental species were collected from the study area and authenticated by the Botanical Survey of India. The collected plant materials were thoroughly cleaned, shade-dried at room temperature, and mechanically powdered. The powdered material was passed through sieve No. 60 to obtain a uniform particle size suitable for extraction. Sequential extraction was performed using solvents of increasing polarity, namely petroleum ether, benzene, ethyl acetate, methanol, ethanol, and distilled water, by the maceration method with intermittent shaking. The extracts obtained were filtered using Whatman No. 1 filter paper and concentrated for further analysis. Among the different extracts, the ethanolic extract was selected for subsequent investigations. For determination of extractive value, 5 g of air-dried powdered material was macerated with 100 mL of the respective solvent for 24 h, followed by filtration. A measured volume (50 mL) of the filtrate was evaporated to dryness and dried at 105°C to constant weight, and the percentage of solvent-soluble extractive value was calculated with reference to the air-dried plant material.
2.3. Animals
Adult male albino Wistar rats (6 weeks), weighing 150 to 200 g were used for the present anti-diabetic study. The animals were housed in clean polypropylene cages and maintained in a well-ventilated temperature controlled animal house with a constant 12 h light/dark schedule. The animals were fed with standard rat pelleted diet and clean drinking water was made available ad libitum. All animal procedures were performed after approval from the ethical committee and in accordance with the recommendations for the proper care and use of laboratory animals.
2.4. Induction of T2DM
The animal divided into six groups of six animals each. The animals are kept overnight fasting and check the initial fasting blood glucose from tip of rat tail vein. Streptozotocin was dissolved in citrate buffer (pH 4.5) and Nicotinamide was dissolved in normal saline. Non-insulin dependent diabetes mellitus was induced in overnight fasted rats by a single intraperitoneal injection of 60 mg/kg Streptozotocin, 15 min after the i.p administration of 120 mg/kg of nicotinamide. Hyperglycemia was confirmed by the elevated levels of blood glucose were determined at 72 h. The animals with blood glucose concentration more than 250mg/dl will be used for the study .
2.5. Experimental Design
Animals were randomly divided into 7 groups with sample size of 6 animals.
1) Group I - Only normal saline
2) Group II- STZ 65 mg/kg/b.w. (i.p) +NIC 120mg/kg (i.p)
3) Group III- STZ (65 mg/kg) NIC 120mg/kg (i.p) rats treated with Metformin 200 mg/kg (p.o)
4) Group IV-STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Extract L.D 200 mg/kg
5) Group V- STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Probiotic
6) Group VI- STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Extract+Probiotic
7) Group VII- STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Probiotic + Metformin 200 mg/kg (p.o)
2.6. Estimation of Blood Glucose
Blood sample were collected from tip of rat tail vein and Glucose levels were estimated using a glucose oxidase-peroxidase reactive strips and a glucometer (Accu-chek, Roche Diagnostics, USA).
2.7. Blood Collection for Biochemical Analysis
Diethyl ether anesthesia was used to puncture the retro-orbital plexus in order to extract blood. Ethylene diamine tetra-acetic acid (EDTA) anticoagulant-containing bottles were used to collect whole blood for haematograms, whilst plain Eppendorf tubes were used to collect samples for biochemical examination. Centrifugation at 1000 rpm for 10 minutes was used to separate the serum, and several biochemical characteristics were examined. Before being examined, the sera were kept in a freezer at 20 degrees Celsius. Serum biomarkers including alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine transaminase (ALT), triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), and very low density lipoprotein (VLDL) were used in the liver function test. Using a kit from Span Diagnostics Limited, India, serum urea was measured as a kidney parameter. .
2.8. Histological Examinations
The pancreas liver was immediately removed, dissected, and cleaned with a cold saline solution. A section of the pancreas and liver were embedded in paraffin after being fixed in a 10% neutral formalin fixative solution and dried in alcohol. A rotary microtome was used to create microtome slices with a thickness of 4–5 μm. To see histological alterations, the slices were stained with hematoxylin and eosin dye.
3. Statistical Analysis
The findings are analyzed using one-way analysis of variance and post-hoc Dunnett's test, with statistical significance set at a value of P < 0.05. The represented data are mean ± standard error of the mean. GraphPad Prism version 5.03 (GraphPad Software, Inc.) was used for statistical analysis.
4. Result
4.1. Body Weight Analysis in Normal and Experimental Rats (in Gms)
Table 1. Effect of Syzygium tamilnadense on Body Weight.

Group

Before Induction of STZ on body weight

After Induction of STZ on body weight

Body Weight on diabetes animals with standard and extract

Initial body weight

body weight on 1st week

body weight on 2nd week

body weight on 3rd week

body weight on 4th week

Control

129±3.3

150±3.02

164±6.4

161±7.11

138±4.73

Only STZ

132±5.93

145±6.31

148±2.08

148±6.88

141±4.2

STZ+ Glibenclamide

127±6.11

148±4.25

153±3.78

152±5.06

158±6.79

STZ+E L 100 mg/kg

119±2.18

147±3.15

159±2.79

160±2.5

156±2.35

STZ+E L 200 mg/kg

138±3.83

158±5.05

172±7.1

161±6.5

161±2.35

STZ+E F 100 mg/kg

131±2.62

142±4.18

161±1.76

165±2.6

172±3.37

STZ+E F 200 mg/kg

138±4.52

148±2.69

163±2.38

165±3.13

171±5.32

STZ-induced diabetic rats exhibited a marked reduction in body weight compared with the normal control group. The body weight of untreated diabetic rats remained low (141 ± 4.20 g at the end of the experiment), whereas treatment with Syzygium tamilnadense significantly improved body weight. The fruit extract at 100 mg/kg and 200 mg/kg increased body weight to 172 ± 3.37 g and 171 ± 5.32 g, respectively, which was higher than the Glibenclamide-treated group (158 ± 6.79 g). These findings indicate that S. tamilnadense effectively prevented diabetes-induced body weight loss.
4.2. Estimation of Blood Glucose in Normal and Experimental Rats (gm/dl)
Table 2. Effect of Syzygium tamilnadense on Blood Glucose Levels.

Group

Before Induction of STZ

After Induction of STZ

Fasting blood sugar level on diabetes animals with standard and extract

Initial fasting blood sugar

Fasting blood sugar on 72hr

Fasting blood sugar on 10th day

Fasting blood sugar on 15th day

Fasting blood sugar on 28th day

Control

80.2±5.61

80.2±13.7

80.2±5.61

80.2±5.61

80.2±5.61

Only STZ

82.2±6.23

405±151

355±31.4

267±36.1

112±35.5

STZ+ Glibenclamide

80.7±3.89

300±75.6

349±50.9

312±81.2

47.2±10.5

STZ+E L 100 mg/kg

74.8±6.95

405±134

276±34.8

357±59.2

98.2±25.8

STZ+E L 200 mg/kg

78.8±6.18

313±87.6

333±32.9

393±60.8

70.7±21.8

STZ+E F 100 mg/kg

90.0±6.2

318±82.6

308±83.1

235±77.1

68.7±23.2

STZ+E F200 mg/kg

87±4.67

317±97.1

213±45.3

197±43.1

79.7±19.4

Following STZ induction, fasting blood glucose increased markedly from 82.2 ± 6.23 mg/dL to 405 ± 151 mg/dL in diabetic rats. Treatment with S. tamilnadense significantly reduced blood glucose levels after 28 days. The fruit extract (100 and 200 mg/kg) reduced blood glucose to 68.7 ± 23.2 mg/dL and 79.7 ± 19.4 mg/dL, respectively, while the leaf extract (200 mg/kg) reduced glucose to 70.7 ± 21.8 mg/dL. These reductions were comparable to Glibenclamide (47.2 ± 10.5 mg/dL), demonstrating significant antihyperglycemic activity.
4.3. HbA1c, Serum Insulin and Glycogen Levels in Normal and STZ- Induced Diabetic Rats
Table 3. Effect of Syzygium tamilnadense on HbA1c, Insulin and Hepatic Glycogen.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

HbA1c (mmol/l)

5.53±0.612

11.5±0.318

5.73±0.203

8.43±0.448

7.67±0.536

8.53±0.546

6.47±0.384

Insulin (uIU/ml)

0.863±0.026

1.33±0.287

0.763±0.0601

1.02±0.114

0.88±0.0231

1.06±0.156

0.857±0.0348

Glycogen (mg/dl)

1.43±0.178

2.23±0.182**

0.899±0.035

1.11±0.186

1.04±0.153

0.844±0.0605*

0.808±0.0916*

Diabetic rats exhibited a significant increase in HbA1c from 5.53 ± 0.61 mmol/L in the control group to 11.5 ± 0.32 mmol/L. Treatment with S. tamilnadense reduced HbA1c to 6.47 ± 0.38 mmol/L in the fruit extract (200 mg/kg) group. Serum insulin and hepatic glycogen levels were also improved following treatment, indicating enhanced insulin secretion and restoration of glucose metabolism.
4.4. Oral Glucose Tolerance Test (OGTT) in Normal and Experimental Rats
Table 4. Effect of Syzygium tamilnadense on Liver Function Markers.

Group

GROUP

Control

Only OGTT

OGTT+ Metformin

OGTT + E L 100 mg/kg

OGTT + E L 200 mg/kg

OGTT + E F 100 mg/kg

Initial Glucose level

58.5±3.52

56.8±3.64

53.5±3.4

60.3±6.86

59.3±3.68

58.5±2.78

55.8±3.71

1sthr

79.3±4.13

267±6.72***

239±3.3***

241±8.2***

228±11.8***

239±14.2***

222±9.43***

2ndhr

76.5±1.55

245±9.86***

198±10.8***

218±14.9***

229±12.2***

234±16.3***

230±11.6***

3rdhr

82±0.408

238±4.77***

201±11***

219±12.4***

218±7.64***

214±8.52***

205±3.51***

4thhr

82±2.68

200±5.49***

175±4.56***

182±9.7***

174±10.1***

176±12.7***

171±7.62***

5thhr

76.5±3.59

175±8.11***

138±4.11***

147±4.19***

150±5.01***

152±4.33***

133±5.91***

6thhr

75.8±1.93

123±6.12***

101±3.73**

119±6.27***

115±2.63***

109±2.8***

101±5.04**

The OGTT revealed significantly impaired glucose tolerance in diabetic rats, with blood glucose reaching 267 ± 6.72 mg/dL after 1 hour and remaining elevated (123 ± 6.12 mg/dL) after 6 hours. Treatment with S. tamilnadense significantly improved glucose tolerance. The fruit extract (200 mg/kg) reduced blood glucose to 101 ± 5.04 mg/dL at 6 hours, which was comparable to the metformin-treated group (101 ± 3.73 mg/dL), confirming its potent glucose-lowering effect.
4.5. Serum Biochemical Marker Enzymes and Liver Function Parameters in Normal and STZ-Induced Diabetic Rats
Table 5. Effect of Syzygium tamilnadense on Kidney Function Markers.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

SGOT (U/L)

51.7±2.03

124±0.882***

95±11.9***

111±2.08***

86±4.62**

102±1.45***

75±4.04**

SGPT (U/L)

44±3.21

42.7±0.882

35.7±0.882

45.7±0.882

29.3±1.76**

49±4.04

38±3.46

ALP (U/L)

131±4.67

145±7

137±24.5

139±4.04

130±3.93

150±3.46

127±2.89

Diabetic rats showed significant hepatic dysfunction, with SGOT increasing from 51.7 ± 2.03 U/L in controls to 124 ± 0.88 U/L. Administration of S. tamilnadense significantly reduced SGOT levels, particularly with the fruit extract (200 mg/kg), which lowered SGOT to 75 ± 4.04 U/L. Similarly, SGPT and ALP values approached normal levels following treatment, confirming the hepatoprotective effect of the extract.
4.6. Kidney Function Markers in STZ-Induced Diabetic Rats
Table 6. Effect of Syzygium tamilnadense on Serum Lipid Profile.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

Urea (mg/dl)

41±1.53

86.7±9.96***

40±0.577

73.3±3.53**

69±7.1*

42.3±2.03

36±3.46

Uric acid (mg/dl)

0.567±0.0882

1.73±0.12**

0.767±0.0882

1.53±0.176**

0.933±0.285

0.9±0.208

0.8±0.153

Creatinine (mg/dl)

0.6333±0.1453

1.833±0.03333**

0.5333±0.08819

1.6±0.2309*

1.233±0.318

0.8667±0.3283

0.7333±0.08819

STZ-induced diabetes significantly increased serum urea, uric acid, and creatinine levels. Serum urea increased from 41 ± 1.53 mg/dL in controls to 86.7 ± 9.96 mg/dL in diabetic rats, while creatinine increased from 0.63 ± 0.15 mg/dL to 1.83 ± 0.03 mg/dL. Treatment with the fruit extract (200 mg/kg) reduced urea to 36 ± 3.46 mg/dL and creatinine to 0.73 ± 0.09 mg/dL, indicating marked nephroprotective activity.
4.7. Lipid Profile in STZ-Induced Diabetic Rats
Table 7. Effect of Syzygium tamilnadense on Haematological Parameters.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

Total Cholesterol (mg/dl)

48.9±3.29

57.7±3.99

38±0.837

54.2±3.01

47.6±4.86

45.2±2.31

42.2±1.76

Triglycerides (TG) (mg/dl)

53.2±4.79

100±0.924***

71.7±1.1

86.4±6.38**

55.8±7.57

83.7±3.41**

55.4±6.09

HDL- Cholesterol (mg/dl)

8.53±0.664

11.5±0.318*

7.4±0.981

8.43±0.448

8±0.862

8.1±0.493

7.73±0.203

Diabetic rats developed dyslipidemia, as evidenced by elevated total cholesterol (57.7 ± 3.99 mg/dL) and triglycerides (100 ± 0.92 mg/dL) compared with the control group (48.9 ± 3.29 mg/dL and 53.2 ± 4.79 mg/dL, respectively). Treatment with S. tamilnadense significantly reduced serum cholesterol and triglycerides. The fruit extract (200 mg/kg) reduced total cholesterol to 42.2 ± 1.76 mg/dL and triglycerides to 55.4 ± 6.09 mg/dL, indicating improved lipid metabolism.
4.8. Hematological Parameters in Normal and STZ-Induced Diabetic Rats
Table 8. Effect of Syzygium tamilnadense on Oxidative Stress and Antioxidant Status.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

RBC (×106/µL)

5.67±0.167

5.48±0.15

5.16±0.0173

5.73±0.101

6.24±0.0722

5.62±0.259

5.35±0.232

WBC (×103/µL)

10.8±0.346

11.3±0.26

13.2±0.549*

13.6±0**

13.5±0.924*

11±0.491

13.1±0.521*

Total Haemoglobin (g/dl)

13.1±0.145

12.6±0.606

10.8±0.203*

13.1±0.0577

13.8±0.145

12.4±0.328

11.9±0.994

Polymorphs (%)

7.67±0.882

6±0.577

6.67±2.03

10±1.15

7±1.15

5±1.15

4.33±1.86

Lymphocytes (%)

85.7±2.6

90±1.15

87±2.31

79±0.577

85.7±1.45

88.3±3.18

86.3±1.45

Diabetic rats exhibited alterations in hematological parameters, including reduced hemoglobin (12.6 ± 0.61 g/dL) compared with the control group (13.1 ± 0.15 g/dL). Treatment with S. tamilnadense improved hemoglobin concentration, reaching 13.8 ± 0.15 g/dL in the leaf extract (200 mg/kg) group. The extract also normalized leukocyte counts and differential leukocyte profiles, indicating improvement in overall physiological status.
4.9. Antioxidant Parameters in Normal and STZ-Induced Experimental Rats
Table 9. Effect of Syzygium tamilnadense on Carbohydrate Metabolic Enzymes.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

Total Protein (mg/dl)

0.791 ± 0.407

1.05 ± 0.194

0.229 ± 0.00318

0.9623 ± 0.2399

0.513 ± 0.227

0.447 ± 0.116

0.313 ± 0.057

SOD (unit/min/Mg protein)

0.146 ± 0.0142

0.4 ± 0.045***

0.109 ± 0.00289

0.205 ± 0.0323

0.181 ± 0.00664

0.166 ± 0.0512

0.124 ± 0.0166

Catalysis (µmole h202/min/mg protein)

0.3 ± 0.0157

0.9 ± 0.114***

0.116 ± 0.0234

0.746 ± 0.0303**

0.363 ± 0.0121

0.307 ± 0.147

0.238 ± 0.0307

GPX (µmoles of glutathione oxidized/min/mg protein)

0.039 ± 0.008544

0.2213 ± 0.03262***

0.05167 ± 0.03982

0.1577 ± 0.007796**

0.142 ± 0.003464*

0.117 ± 0.008185

0.075 ± 0.006928

GSH (µg/mg protein)

0.179 ± 0.00733

0.469 ± 0.0661***

0.0827 ± 0.0367

0.326 ± 0.0468

0.273 ± 0.0367

0.163 ± 0.0347

0.146 ± 0.00611

LPO (nmol of MDA /mg protein)

0.0757 ± 0.0012

0.148 ± 0.00866***

0.07 ± 0.00451

0.103 ± 0.00968*

0.0873 ± 0.00145

0.083 ± 0.00866

0.0807 ± 0.00426

STZ-induced diabetes caused marked oxidative stress, reflected by increased lipid peroxidation (LPO) from 0.0757 ± 0.0012 to 0.148 ± 0.0087 nmol MDA/mg protein. Treatment with S. tamilnadense significantly reduced LPO to 0.0807 ± 0.0043 nmol MDA/mg protein in the fruit extract (200 mg/kg) group. In addition, antioxidant enzyme activities, including SOD, catalase, GPx, and GSH, were markedly improved, demonstrating potent antioxidant activity.
4.10. Carbohydrate Metabolic Enzymes in Normal and STZ-Induced Diabetic Rats
Table 10. Effect of Syzygium tamilnadense on Oral Glucose Tolerance.

Group

Control (CMC)

Only STZ

STZ+ Glibenclamide

STZ+E L 100 mg/kg

STZ+E L 200 mg/kg

STZ+E F 100 mg/kg

STZ+E F 200 mg/kg

Glucokinase (unit/min/mg protein)

0.875 ± 0.032

0.913 ± 0.0358

0.493 ± 0.0917**

0.664 ± 0.000882

0.467 ± 0.0607***

0.45 ± 0.064***

0.424 ± 0.0502***

Hexokinase (unit/min/mg protein)

1.3 ± 0.00866

0.591 ± 0.153

0.524 ± 0.0242

0.647 ± 0.136

0.585 ± 0.0285

0.578 ± 0.041

0.53 ± 0.0876

Glucose-6- Phosphatase (nmoles of piliberated /min/mg protein)

0.1187 ± 0.01157

0.242 ± 0.02859***

0.182 ± 0.01179

0.1823 ± 0.01068

0.1543 ± 0.01495

0.172 ± 0.008888

0.1503 ± 0.01313

Fructose 1-6- Di Phosphatase (nmoles of piliberated /min/mg protein)

0.503 ± 0.0429

0.737 ± 0.112

0.488 ± 0.0987

0.465 ± 0.0616

0.426 ± 0.0303

0.362 ± 0.0549

0.26 ± 0.0485

Diabetes significantly altered the activities of carbohydrate metabolic enzymes. Glucose-6-phosphatase activity increased from 0.1187 ± 0.0116 in controls to 0.242 ± 0.0286 nmol/min/mg protein in diabetic rats, while hexokinase activity decreased from 1.30 ± 0.0087 to 0.591 ± 0.153 unit/min/mg protein. Treatment with S. tamilnadense restored these enzyme activities toward normal values, indicating improved glucose utilization and reduced hepatic glucose production.
Statistical comparison (Tables 1-10): Each group (n=6), each value represents Mean ± SEM. One way ANOVA, followed by Dunnett comparison was performed. (***P<0.001) control group was compared with Only STZ group-II. (***P<0.001-**P<0.01, *P<0.05) treated groups III, IV, V, VI and VII was compared with group I.
Figure 1. Body Weight Analysis of Normal and Experimental Rats (g).
Figure 2. Liver Histopathological Examination.
A - Only normal saline
B - STZ 65 mg/kg/b.w. (i.p) +NIC 120mg/kg (i.p)
C – STZ (65 mg/kg) NIC 120mg/kg (i.p) rats treated with Metformin 200 mg/kg (p.o)
D - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Extract L.D 200 mg/kg
E - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Probiotic
F - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Extract+Probiotic
G - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Probiotic + Metformin 200 mg/kg (p.o)
Figure 3. Pancreas Histopathological Examination.
A - Only normal saline
B - STZ 65 mg/kg/b.w. (i.p) +NIC 120mg/kg (i.p)
C – STZ (65 mg/kg) NIC 120mg/kg (i.p) rats treated with Metformin 200 mg/kg (p.o)
D - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Extract L.D 200 mg/kg
E - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Probiotic
F - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Extract+Probiotic
G - STZ (65 mg/kg) +NIC 120mg/kg (i.p) rats treated with Probiotic + Metformin 200 mg/kg (p.o)
5. Discussion
As presented in Tables 1-10, the ethanolic extract of Syzygium tamilnadense significantly ameliorated diabetes-induced metabolic disturbances in nicotinamide–streptozotocin (NA-STZ)-induced type 2 diabetic rats. This experimental model, characterized by partial pancreatic β-cell destruction and insulin resistance, closely mimics human type 2 diabetes and produced marked hyperglycaemias, impaired glucose tolerance, reduced body weight, elevated glycated haemoglobin (HbA1c), altered insulin secretion, depleted hepatic glycogen, and disrupted carbohydrate-metabolizing enzymes . Untreated diabetic rats showed significant body weight loss (141 ± 4.20 g), whereas treatment with S. tamilnadense restored body weight to 172 ± 3.37 g and 171 ± 5.32 g at fruit extract doses of 100 and 200 mg/kg, respectively, exceeding Glibenclamide (158 ± 6.79 g). Fasting blood glucose increased from 82.2 ± 6.23 mg/dL to 405 ± 151 mg/dL in diabetic rats but declined to 68.7 ± 23.2, 79.7 ± 19.4, and 70.7 ± 21.8 mg/dL following treatment with fruit (100 and 200 mg/kg) and leaf (200 mg/kg) extracts, respectively, comparable to Glibenclamide (47.2 ± 10.5 mg/dL). HbA1c decreased from 11.5 ± 0.32 to 6.47 ± 0.38 mmol/L after fruit extract (200 mg/kg) treatment, with concurrent restoration of serum insulin and hepatic glycogen levels, indicating improved β-cell function and glucose metabolism . The oral glucose tolerance test demonstrated improved glucose homeostasis, with blood glucose decreasing from 267 ± 6.72 mg/dL at 1 h to 101 ± 5.04 mg/dL at 6 h in the fruit extract (200 mg/kg) group, comparable to metformin (101 ± 3.73 mg/dL) . Consistent with previous reports on antioxidant-mediated antidiabetic effects of medicinal plants , S. tamilnadense also normalized glucose-6-phosphatase activity (0.242 ± 0.0286 to near normal from the diabetic value) and restored hexokinase activity (0.591 ± 0.153 unit/min/mg protein toward the control value of 1.30 ± 0.0087 unit/min/mg protein), indicating enhanced glycolysis, reduced hepatic gluconeogenesis, improved insulin sensitivity, and better peripheral glucose utilization .
In addition to its antihyperglycemic effects, S. tamilnadense exhibited significant hepatoprotective, nephroprotective, hypolipidemic, and hepatoprotective activities (Tables 4-7). Diabetes-induced hepatic injury, reflected by elevated SGOT (51.7 ± 2.03 to 124 ± 0.88 U/L), was significantly attenuated by the fruit extract (200 mg/kg), reducing SGOT to 75 ± 4.04 U/L, while SGPT and ALP also approached normal levels, indicating restoration of hepatic function . Renal dysfunction, evidenced by increased serum urea (41 ± 1.53 to 86.7 ± 9.96 mg/dL) and creatinine (0.63 ± 0.15 to 1.83 ± 0.03 mg/dL), was significantly improved following fruit extract treatment, reducing these values to 36 ± 3.46 mg/dL and 0.73 ± 0.09 mg/dL, respectively . The extract also corrected diabetes-associated dyslipidaemia by reducing total cholesterol from 57.7 ± 3.99 to 42.2 ± 1.76 mg/dL and triglycerides from 100 ± 0.92 to 55.4 ± 6.09 mg/dL, suggesting improved lipid metabolism and insulin sensitivity . Furthermore, reduced haemoglobin levels in diabetic rats (12.6 ± 0.61 g/dL) were restored to 13.8 ± 0.15 g/dL by the leaf extract (200 mg/kg), accompanied by normalization of leukocyte profiles, indicating recovery of haematological homeostasis and reduced oxidative damage . Collectively, these findings demonstrate that S. tamilnadense exerts multifunctional antidiabetic effects by improving glycemic control, regulating carbohydrate metabolism, and protecting against hepatic, renal, lipid metabolic, and haematological complications, supporting its potential as a promising natural therapeutic agent for type 2 diabetes mellitus.
6. Conclusion
The present study demonstrates that Syzygium tamilnadense possesses significant antidiabetic activity in nicotinamide–streptozotocin-induced type 2 diabetic rats. The extract effectively improved glycemic control by reducing blood glucose and HbA1c levels, enhancing insulin secretion, restoring body weight, improving glucose tolerance, normalizing lipid metabolism, and protecting hepatic and renal functions. It also alleviated oxidative stress and promoted pancreatic β-cell and liver tissue recovery. Overall, these findings suggest that S. tamilnadense is a promising natural therapeutic candidate for the management of type 2 diabetes mellitus and its associated complications.
Abbreviations

ALP

Alkaline Phosphatase

AST

Aspartate Aminotransferase

ALT

Alanine Transaminase

DM

Diabetes Mellitus

EDTA

Ethylene Diamine Tetra Acetic Acid

HbA1c

Haemoglobin A1c

HDL

High Density Lipoprotein

NIC

Nicotinamide

OGTT

Oral Glucose Tolerance Test

TG

Triglycerides

TC

Total Cholesterol

VLDL

Very Low Density Lipoprotein

NA-STZ

Nicotinamide–Streptozotocin

STZ

Streptozotocin

Acknowledgments
The authors would like to thank Faculty of Botany Department, LRG Government Arts College for Women, and Mr. R. Prakash Forest Official and those who have assisted with fieldwork.
Author Contributions
Mani Jayendran: Conceptualization, Software, Writing – original draft
Coimbatore Murugesan Ganesan: Investigation, Validation, Writing – review & editing
Thangamani Balasaravanan: Data curation, Project administration, Resources
Data Availability Statement
The data generated and/or analysed during this study are available from the corresponding author upon reasonable request.
Conflicts of Interest
The authors declare no conflicts of interest.
References
[1] Dey P, Kundu A, Chakraborty HJ, Kar B, Choi WS, Lee BM, Bhakta T, Atanasov AG. Antidiabetic phytochemicals from medicinal plants: Prospective candidates for new drug discovery and development. Front Endocrinol (Lausanne). 2022; 3: 800714.
[2] Anshika, Pandey RK, Singh L, Kumar S, Singh P, Pathak M, Jain S. Plant bioactive compounds and their mechanistic approaches in the treatment of diabetes: a review. Future Journal of Pharmaceutical Sciences. 2022; (1): 52.
[3] Vishwakarma A, Biswas V, Hasan F, Praveen A, Sharma D. Diabetes mellitus: An updated overview and role of medicinal plants in modern treatment. Innov Med Omics. 2025; 2(2): 20-35.
[4] Uddin ABMN, Hossain F, Reza ASMA, Nasrin MS, Alam AHMK. Traditional uses, pharmacological activities, and phytochemical constituents of the genus Syzygium: A review. Food Sci Nutr. 2022; 10(6): 1789-1819.
[5] Youssef SA, Elosaily AH, Farag NF, Selim NM, Hussein MA, El Hefnawy HM. Syzygium australe extracts exhibit significant antioxidant and antidiabetic properties: A comprehensive analysis of the phytoconstituents. Future J Pharm Sci. 2025; 1: 55.
[6] Suksri K, Muangchan N, Yingngam B, Kaewkanlaya P, Onthamma J, Bootmart Y, Pusinam C, Chaipipattanamongkol N, Sridakhot K, Sripukdee S, Kaokaew J. Syzygium samarangense fruit extract attenuates hyperglycemia in type 2 diabetic rats through modulation of oxidative stress and inflammation. Biomed Rep. 2025; 3(4): 163.
[7] American Diabetes Association Professional Practice Committee. Standards of care in diabetes—2025. Diabetes Care. 2025; 8(Suppl 1): S1-S352.
[8] Chayarop K, Peungvicha P, Temsiririrkkul R, Wongkrajang Y, Chuakul W, Rojsanga P. Hypoglycaemic activity of Mathurameha, a Thai traditional herbal formula aqueous extract, and its effect on biochemical profiles of streptozotocin-nicotinamide-induced diabetic rats. BMC Complement Altern Med. 2017; 7: 383.
[9] Uçar Baş K, Güneş E, Çakır A. Therapeutic prospects of phytochemicals in diabetes: Insights from recent clinical evidence. Endokrynol Pol. 2025; 6(6): 586-593.
[10] Sivakumar A, Thanu AS, Vishnumukkala T, Ganesh KSVAB. Management of diabetes mellitus using medicinal plants: A review. Bioinformation. 2024; 0(7): 705-710.
[11] Ashagrie YN, Chaubey KK, Tadesse MG, Dayal D, Bachheti RK, Rai N, et al. Antidiabetic phytochemicals: An overview of medicinal plants and their bioactive compounds in diabetes mellitus treatment. Z Naturforsch C J Biosci. 2025; 80(9-10):457-479.
[12] Rajan S, Jayendran M, Sethuraman M. Folk herbal practices among Toda tribe of the Nilgiri Hills in Tamil Nadu, India. J Nat Remedies. 2005; 5(1): 52-58.
[13] Rampura ZF, Panwar SS. Herbal antidiabetics: An evidence-based review of medicinal plants used in type 2 diabetes. J Pharmacogn Phytochem. 2025; 4(5): 250-257.
[14] Araújo ANV, Souza EL, Nascimento DS, Alves JM, Sampaio KB, Silva SRF, Alves JLB, Albuquerque TMR. Revisiting the nutritional and functional value and health-promoting potential of Syzygium species. Journal of Functional Foods. 2024; 18: 106265.
[15] Dogara AM, Bradosty SW, Al-Zahrani AA, Hamad SW, Almalki HD. Ethnobotany, bioactive compounds and pharmacology of Syzygium guineense (Willd.) DC: A review. Journal of Ethnopharmacology. 2025; 39: 119149.
[16] Chandran R, Parimelazhagan T, Shanmugam S, Thankarajan S. Antidiabetic activity of Syzygium calophyllifolium in streptozotocin-nicotinamide induced type 2 diabetic rats. Biomed Pharmacother. 2016; 2: 547-554.
[17] Clemente-Suárez VJ, Martín-Rodríguez A, Beltrán-Velasco AI, Rubio-Zarapuz A, Martínez-Guardado I, Valcárcel-Martín R, Tornero-Aguilera JF. Functional and Therapeutic Roles of Plant-Derived Antioxidants in Type 2 Diabetes Mellitus: Mechanisms, Challenges, and Considerations for Special Populations. Antioxidants (Basel). 2025 Jun 13; 4(6): 725.
[18] Ahmed I, Adeghate E, Cummings E, Sharma AK, Singh J. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem. 2004; 261(1-2): 63-70.
[19] Dey L, Attele AS, Yuan CS. Alternative therapies for type 2 diabetes. Altern Med Rev. 2002; (1): 45-58.
[20] El-Hawary SS, Yassin NA, Abdel-Monem AR. Protective effects of medicinal plant antioxidants against diabetes-induced hepatic and renal dysfunction. Biomed Pharmacother. 2022; 46: 112537.
[21] Karthick K, Suresh Kumar R, Mohanraj K. Role of phenolics and flavonoids in glycemic control and antioxidant defense in diabetic conditions. S Afr J Bot. 2023; 56: 98-107.
[22] Sharma V, Meena R, Gupta P. Nano-herbal formulations for diabetes mellitus: Improved bioavailability and therapeutic efficacy. Int J Biol Macromol. 2025; 76: 130987.
[23] Cock IE, Cheesman M. The medicinal properties and phytochemistry of plants of the genus Syzygium. Curr Tradit Med. 2018; (1): 50-75.
[24] Rathakrishnan N, Chitra V. Syzygium tamilnadense: A new species from the Western Ghats, Tamil Nadu, India. Int J Adv Res. 2014; (9): 101-105.
Cite This Article
  • APA Style

    Jayendran, M., Ganesan, C. M., Balasaravanan, T. (2026). Evaluation of the Antihyperglycemic Activity of Ethanolic Extracts of Syzygium tamilnadense in Nicotinamide–Streptozotocin-Induced Type 2 Diabetic Rats. Journal of Diseases and Medicinal Plants, 12(3), 117-127. https://doi.org/10.11648/j.jdmp.20261203.13

    Copy | Download

    ACS Style

    Jayendran, M.; Ganesan, C. M.; Balasaravanan, T. Evaluation of the Antihyperglycemic Activity of Ethanolic Extracts of Syzygium tamilnadense in Nicotinamide–Streptozotocin-Induced Type 2 Diabetic Rats. J. Dis. Med. Plants 2026, 12(3), 117-127. doi: 10.11648/j.jdmp.20261203.13

    Copy | Download

    AMA Style

    Jayendran M, Ganesan CM, Balasaravanan T. Evaluation of the Antihyperglycemic Activity of Ethanolic Extracts of Syzygium tamilnadense in Nicotinamide–Streptozotocin-Induced Type 2 Diabetic Rats. J Dis Med Plants. 2026;12(3):117-127. doi: 10.11648/j.jdmp.20261203.13

    Copy | Download

  • @article{10.11648/j.jdmp.20261203.13,
      author = {Mani Jayendran and Coimbatore Murugesan Ganesan and Thangamani Balasaravanan},
      title = {Evaluation of the Antihyperglycemic Activity of Ethanolic Extracts of Syzygium tamilnadense in 
    Nicotinamide–Streptozotocin-Induced Type 2 Diabetic Rats},
      journal = {Journal of Diseases and Medicinal Plants},
      volume = {12},
      number = {3},
      pages = {117-127},
      doi = {10.11648/j.jdmp.20261203.13},
      url = {https://doi.org/10.11648/j.jdmp.20261203.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jdmp.20261203.13},
      abstract = {Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. Prolonged hyperglycemia is associated with oxidative stress, dyslipidemia, and progressive damage to vital organs, highlighting the need for safer and more effective therapeutic agents. Syzygium tamilnadense Rathakr. & Chitra, an endemic medicinal species of the Western Ghats, India, has been traditionally used for various therapeutic purposes; however, its antidiabetic potential has not been scientifically validated. To the best of our knowledge, this is the first scientific exploration of its medicinal potential. The present study aimed to evaluate the antihyperglycemic, antioxidant, and organ-protective effects of the ethanolic extract of S. tamilnadense in nicotinamide–streptozotocin-induced type 2 diabetic rats. Experimental diabetes was induced using nicotinamide and streptozotocin, followed by oral administration of different doses of the ethanolic extract for four weeks. Fasting blood glucose, oral glucose tolerance, glycated hemoglobin (HbA1c), serum insulin, hepatic glycogen, lipid profile, antioxidant enzymes, hepatic and renal function biomarkers, and histopathological changes in pancreatic and hepatic tissues were evaluated. Treatment with S. tamilnadense significantly reduced fasting blood glucose and HbA1c levels, improved glucose tolerance, restored serum insulin and hepatic glycogen levels, normalized serum lipid profiles, and enhanced body weight compared with diabetic controls. The extract also improved endogenous antioxidant defense, attenuated oxidative stress, and significantly ameliorated hepatic and renal dysfunction. Histopathological examination further demonstrated marked regeneration of pancreatic β-cells and restoration of normal hepatic architecture in treated animals. The higher-dose treatment exhibited therapeutic efficacy comparable to the standard antidiabetic drug. These findings demonstrate that the ethanolic extract of S. tamilnadense possesses significant antihyperglycemic, antioxidant, hepatoprotective, and nephroprotective activities, suggesting its potential as a promising natural therapeutic candidate for the management of type 2 diabetes mellitus. Further studies are warranted to isolate the bioactive constituents and elucidate the underlying molecular mechanisms.},
     year = {2026}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Evaluation of the Antihyperglycemic Activity of Ethanolic Extracts of Syzygium tamilnadense in 
    Nicotinamide–Streptozotocin-Induced Type 2 Diabetic Rats
    AU  - Mani Jayendran
    AU  - Coimbatore Murugesan Ganesan
    AU  - Thangamani Balasaravanan
    Y1  - 2026/08/27
    PY  - 2026
    N1  - https://doi.org/10.11648/j.jdmp.20261203.13
    DO  - 10.11648/j.jdmp.20261203.13
    T2  - Journal of Diseases and Medicinal Plants
    JF  - Journal of Diseases and Medicinal Plants
    JO  - Journal of Diseases and Medicinal Plants
    SP  - 117
    EP  - 127
    PB  - Science Publishing Group
    SN  - 2469-8210
    UR  - https://doi.org/10.11648/j.jdmp.20261203.13
    AB  - Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. Prolonged hyperglycemia is associated with oxidative stress, dyslipidemia, and progressive damage to vital organs, highlighting the need for safer and more effective therapeutic agents. Syzygium tamilnadense Rathakr. & Chitra, an endemic medicinal species of the Western Ghats, India, has been traditionally used for various therapeutic purposes; however, its antidiabetic potential has not been scientifically validated. To the best of our knowledge, this is the first scientific exploration of its medicinal potential. The present study aimed to evaluate the antihyperglycemic, antioxidant, and organ-protective effects of the ethanolic extract of S. tamilnadense in nicotinamide–streptozotocin-induced type 2 diabetic rats. Experimental diabetes was induced using nicotinamide and streptozotocin, followed by oral administration of different doses of the ethanolic extract for four weeks. Fasting blood glucose, oral glucose tolerance, glycated hemoglobin (HbA1c), serum insulin, hepatic glycogen, lipid profile, antioxidant enzymes, hepatic and renal function biomarkers, and histopathological changes in pancreatic and hepatic tissues were evaluated. Treatment with S. tamilnadense significantly reduced fasting blood glucose and HbA1c levels, improved glucose tolerance, restored serum insulin and hepatic glycogen levels, normalized serum lipid profiles, and enhanced body weight compared with diabetic controls. The extract also improved endogenous antioxidant defense, attenuated oxidative stress, and significantly ameliorated hepatic and renal dysfunction. Histopathological examination further demonstrated marked regeneration of pancreatic β-cells and restoration of normal hepatic architecture in treated animals. The higher-dose treatment exhibited therapeutic efficacy comparable to the standard antidiabetic drug. These findings demonstrate that the ethanolic extract of S. tamilnadense possesses significant antihyperglycemic, antioxidant, hepatoprotective, and nephroprotective activities, suggesting its potential as a promising natural therapeutic candidate for the management of type 2 diabetes mellitus. Further studies are warranted to isolate the bioactive constituents and elucidate the underlying molecular mechanisms.
    VL  - 12
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Abstract
  • Keywords
  • Document Sections

    1. 1. Introduction
    2. 2. Materials and Methods
    3. 3. Statistical Analysis
    4. 4. Result
    5. 5. Discussion
    6. 6. Conclusion
    Show Full Outline
  • Abbreviations
  • Acknowledgments
  • Author Contributions
  • Data Availability Statement
  • Conflicts of Interest
  • References
  • Cite This Article
  • Author Information